MEDIFAST (MED) – SURVIVAL IN THE ERA OF OZEMPIC?Medifast, Inc.BATS:MEDSimeonNikolaev-investThe company that dominated the weight loss market is now in the midst of its biggest crisis. But is the bottom near? What do the numbers say? ✅ Iron balance sheet: Zero debt and $150 million in cash. Medifast has the resources to fight. ✅ Low valuation: P/E below 6x is levels we usually see for companies on the verge of bankruptcy, and the Altman Z-Score says MED is financially sound. ✅ New strategy: Partnership with LifeMD brings the company into the medical weight loss market. 🛑 The big risk: Revenue falls 45% YoY. Customers are replacing diet shakes with injections. 🎯 Conclusion: MED is for those who believe that traditional diets will find their place alongside new drugs.